Novo Nordisk to license experimental GLP-1 pill from China's Hengrui
Direct Source Verification:
This story is aggregated from Reuters (reuters.com). Full reporting rights and copyright belong to the primary publisher.
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui Reuters
Original Source
https://www.reuters.com/legal/litigation/chinas-hengrui-inks-up-26-billion-deal-with-novo-nordisk-obesity-drug-2026-09-29/
